Update from the GAVI Alliance

Seth Berkley, MD
Chief Executive Officer

Strategic Advisory Group of Experts on Immunization (SAGE)
Geneva, Switzerland, 9-11 April 2013
Update from the GAVI Alliance

- Support to countries
- Policy and market shaping update
- Polio and supplementary immunization activities
- Looking forward
- Mid-term review and replenishment cycle
Support to countries
Vaccine introductions since GAVI start

- **6 programs**: Penta, YF, PCV, RV, MenA, MSD
- **70 countries** (out of 73)
- **152 introductions** (131 routine, 21 SIAs)
- **370 million** children immunised
- **~1 billion** doses distributed
- **46%** coverage Penta 3rd dose
2013 vaccine introductions outlook

- **3** new programs: HPV, MR, Measles SIAs
- **2** more countries: Indonesia, Somalia (72 out of 73)
- **47 to 60** introductions (24-37 routine, 16 SIAs, 7 demos)
- **550 million doses** to be distributed in the year
- **50%** coverage Penta 3\textsuperscript{rd} dose
Health Systems Strengthening (HSS) Support

- HSS support remains critical to achieving GAVI’s mission
- HSS model streamlined – now more relevant and result driven
  - Increasing disbursements to countries due to:
    - Intensified oversight from Secretariat and partners
    - More efficient implementation of fiduciary risk management procedures
- Quality of new HSS proposals improving - higher approval rates
- More frequent reprogramming of old HSS grants to make them more immunisation focused
- New HSS proposals demonstrate strong focus on immunisation (eg, service delivery, supply chain, HR)
Health Systems Strengthening – going forward

- Greater focus on:
  - Sustainability of HSS investments
  - Integration of routine, polio and campaigns into national health systems
  - Seeking synergies with other health strengthening efforts focusing on maternal and child health

- Better technical support and capacity building in countries – focus on implementation and results; RFP for new partners

- More effective collaboration under the International Health Partnership (IHP+) framework respecting the principles of development effectiveness

- Tailored approach to countries
Areas where GAVI is behind on targets

Pneumo, Rota and Penta new introductions
(Cumulative number of country introductions)

Coverage
DTP3 coverage (%)

Equity
% of GAVI countries with no significant difference in coverage across wealth quintiles

2011 + 2012 delays as a result of supply constraints and country readiness
Dedicated focus on countries with coverage and equity issues

<table>
<thead>
<tr>
<th>Equity priority countries</th>
<th>Coverage priority countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yemen</td>
<td>Afghanistan</td>
</tr>
<tr>
<td>India</td>
<td>DRC</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Haiti</td>
</tr>
<tr>
<td>Mozambique</td>
<td>Mauritania</td>
</tr>
<tr>
<td>Vietnam</td>
<td>PNG</td>
</tr>
<tr>
<td>Madagascar</td>
<td>Somalia</td>
</tr>
</tbody>
</table>

- UNICEF lead
- WHO lead
- New entity lead in 6 countries
- Uganda
- Guinea
- South Sudan
- Ethiopia
- Cote d’Ivoire
- Cameroon
- Timor Leste
Update on HPV

- **National introduction**: 2 countries applied in 2012 (Rwanda and Uganda)

- **Demonstration projects**:
  - Interest exceeding expectations
  - Applications in 2012 from 15 countries, 8 approved
  - 7 countries planning to start demonstration projects in 2013 (Ghana, Kenya, Lao PDR, Madagascar, Malawi, Niger, Sierra Leone).
  - An additional 15 applications expected in 2013
GAVI’s commitment to measles spans 4 dimensions

- **Measles second dose**
- **Measles-Rubella campaigns** *(below 15 years) before start of routine*
- **Measles SIA**
  
  6 high risk countries for population below 5 years of age

- **Outbreak response**
  
  fund to Measles Rubella Initiative
  
  (US$ 55m for period 2013-2017)
## Status of measles support - end 2013

### Measles Second Dose

<table>
<thead>
<tr>
<th>Countries</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viet Nam</td>
<td>2007-2011</td>
</tr>
<tr>
<td>DPR of Korea</td>
<td>2008-2012</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>2012</td>
</tr>
<tr>
<td>Cambodia</td>
<td>2012</td>
</tr>
<tr>
<td>Eritrea</td>
<td>2012</td>
</tr>
<tr>
<td>Gambia</td>
<td>2012</td>
</tr>
<tr>
<td>Ghana</td>
<td>2012</td>
</tr>
<tr>
<td>Myanmar</td>
<td>2012</td>
</tr>
<tr>
<td>Burundi</td>
<td>2013</td>
</tr>
<tr>
<td>Zambia</td>
<td>2013 (April)</td>
</tr>
<tr>
<td>Sao Tome and Principe</td>
<td>2013 (October)</td>
</tr>
<tr>
<td>Tanzania</td>
<td>2014 (January)</td>
</tr>
<tr>
<td>Kenya</td>
<td>Self-financing</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>Resubmission</td>
</tr>
</tbody>
</table>

### Measles Rubella SIAs

<table>
<thead>
<tr>
<th>Countries</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangladesh</td>
<td>2013 (August)</td>
</tr>
<tr>
<td>Cambodia</td>
<td>2013 (October)</td>
</tr>
<tr>
<td>Ghana</td>
<td>2013 (October)</td>
</tr>
<tr>
<td>Lao PDR</td>
<td>Only intro grant</td>
</tr>
<tr>
<td>Nepal</td>
<td>Only intro grant</td>
</tr>
<tr>
<td>Rwanda</td>
<td>2013</td>
</tr>
<tr>
<td>Senegal</td>
<td>2013 (October)</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>2013 (October)</td>
</tr>
<tr>
<td>Yemen</td>
<td>2014</td>
</tr>
</tbody>
</table>

### Measles SIAs

<table>
<thead>
<tr>
<th>Countries</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethiopia</td>
<td>2013 (June)</td>
</tr>
<tr>
<td>Pakistan</td>
<td>2013 (June)*</td>
</tr>
<tr>
<td>Nigeria</td>
<td>2013 (August)</td>
</tr>
<tr>
<td>DRC</td>
<td>2013 (September)</td>
</tr>
</tbody>
</table>

* Pending approval
Policy and market shaping update
Vaccine Investment Strategy 2013

To enable upfront, evidence-based decisions about GAVI’s future vaccine investments in order to align planning by countries, industry and donors for the introduction of new, priority vaccines

- WHO landscape analysis identified 15 vaccines as starting point
- Two phases:
  - I: Board decision on strategic direction to inform prioritization of vaccines for further analysis (Jun 2013)
  - II: Board decision on new vaccine priorities 2015-19 (Nov 2013)
- All existing commitments are maintained (pneumo, rota, HPV, JE typhoid, rubella…)
- Implementation of future vaccines pending WHO guidance and resource mobilization outcomes
Policy and evaluation

- Two policy reviews underway:
  - **Gender Policy review:**
    - Based on results from external evaluation, country case studies, country and stakeholder consultations
  - **Transparency & Accountability Policy review:**
    - Based on desk review, country and stakeholder consultations through survey, interviews and focal group discussions
    - Both reviews will be presented to Board November 2013
- **Two key evaluations in 2012**
  - AMC process and design
  - China - HepB
Market Shaping update

- **Tenders**
  - **Pentavalent**
    - Tender completed for 2013-16
    - Manufacturer base is expanding
  - **HPV**
    - Tender completed
    - First demonstration projects to begin shortly
  - **PCV**
    - Tender in progress
    - Awards expected Q2
Polio and supplementary immunization activities
In December 2012, the GAVI Alliance Board:

- Approved GAVI playing a complementary role to the GPEI in the polio eradication effort, specifically through routine immunisation within GAVI’s strategy and mission using existing structures, processes, and procedures.

- Approved GAVI exploring the suitability and possible use of IFFIm as one potential financing mechanism to support this activity within GAVI’s strategy and mission using existing structures, processes, and procedures.
Thinking about complementary approaches

- The WHA polio eradication resolution (1988) wisely: “EMPHASIZES that eradication efforts should be pursued in ways which strengthen the development of the Expanded Programme on Immunization as a whole, fostering its contribution, in turn, to the development of the health infrastructure and of primary health care”; (No mention of SIAs in original resolution)

- Determining “what” to do since 1993

- Learning “how” to do it
Proposed areas for GAVI’s complementary approach

- **Objective**
  
  *To improve immunisation services in accordance with GAVI’s mission and goals while supporting polio eradication by harnessing the complementary strengths of GAVI and GPEI in support of countries*

- **Components include**
  
  - Programmatic - Global & Country
  - IPV implementation (Board decision November 2013)
  - Advocacy and Communications with consistent messages
  - Mobilising resources through innovative financing instruments
Timing and next steps on GAVI’s approach

- Iterative approach
  - Consultations with partners and GPEI (Dec-Apr)
  - Consultation draft of approach document (early Apr)
  - GAVI Programme and Policy Committee for guidance (April)

- In parallel
  - Take overall approach to PPC and circulate revised draft to partners
  - Develop workplans with specific countries (Nigeria, Pakistan, others?)

- Revise as we learn
Re-thinking GAVI and SIAs

- GAVI’s role in planned SIAs
  - Accelerate population immunity: YF, Men A, MR, M, and JE
- Outbreaks & emerging needs supported through other partners (ICG, WHO, MRI)
- SIAs should strengthen immunisation services (already included in M SIA applications)
  - WHO, supported analyses of John Snow Inc.
  - Lessons from countries (eg, North India; Ethiopia “Best practices SIA”)
SIAs strengthening routine immunisation

- Modify guidelines for 2013 new vaccine applications requiring all SIAs to strengthen routine immunisation services
  - Build upon WHO/JSI technical guidance
  - Consider requiring coverage survey and/or evaluation of impact on routine immunisation
- Further discussion with Alliance members on approach and funding implications
- Encourage SAGE to call upon countries and partners supporting SIAs to require concrete activities to strengthen immunisation
Looking forward: Data quality, value of vaccines, supply chain and post-2015
Looking forward:
Data Quality Summit – January 2013

- Strengthen country systems and capacities
- Improve survey design, frequency, methods and content
- Advance innovation in use of biomarkers, technology and triangulation
Looking forward: Value of Vaccines meeting – January 2013

- Shift focus from mortality to: morbidity, disability, social and economic benefits, development, equity
- Need more empirical data (eg, equity, cognitive function)
- Better leverage existing data sources (eg, clinical trials/HDSS sites)
- Value in continuing to convene community
- Meeting report, documents, etc available at www.gavialliance.org/about/value/
- Encourage other research funders
Looking forward: Supply Chain

- Identified as a strategic priority

- Two phases of work:
  - Phase 1: Landscape Analysis
  - Phase 2: Strategy Development

- Example of priority projects underway:
  - Standardised barcodes for vaccine packaging
  - Cold chain equipment procurement project

- End to End Supply Chain strategy for Nov 2013 Board meeting
Looking forward: Post 2015 framework

- Last 1000 days of MDGs – accelerate roll-out of high-impact interventions
- Ensure health is central to the post-2015 agenda
- Promote bold and ambitious indicators – eg, fully immunised child
- Promote value of innovative partnerships
A fully immunised child: promoting bold and ambitious indicators

- Routine immunisation proxy measure of health system
- DPT has been indicator since 1970s
- FIC shifts focus from vial to child
- Applicable to all countries, rich and poor
  - WHO recommends 11 infant antigens
- Modernise and reset ambition
  - DTP3 ~80%; FIC ~5%
Mid-Term Review (MTR) and replenishment cycle
The MTR is a step in the replenishment process towards sustainable long-term funding of GAVI programmes towards saving lives and protecting health.
Delivering on the Promise: Objectives and expected outcomes

- Report back on results and challenges
  - Progress on targets and indicators across 4 strategic goals
  - Discuss how to jointly mitigate challenges

- Build confidence - we are delivering on our promise and our commitments for the future

- Build momentum to second replenishment

- Explore ideas for GAVI’s strategy beyond 2011-2015
Delivering on the Promise: Key messages

- GAVI Alliance is delivering on its promise
- The Alliance demonstrates:
  - results, value for money and return on investment
  - a sustainable business model for development
  - an innovative public private partnership
- Long-term, predictable funding is critical to GAVI’s business of saving lives and protecting people’s health
Back up slides
Association between health and wealth through vaccination

1. Direct and indirect effect of vaccination

2. Better education and cognitive development

3. Healthier/productive workforce

4. Higher savings and investment rates

5. Better survival rates and low fertility rates

6. Healthier communities people want to live in rather than to escape

7. Healthy population attract more foreign investments and trade

Value of Vaccines

http://vimeo.com/54622184